Cargando…

Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia

Schizophrenia (SCZ) is a psychotic syndrome with well-defined signs and symptoms but indecisive causes and effective treatment. Unknown underpinning reasons and no cure of the disease profoundly elevate the risk of illness. Gut microbial dysbiosis related metabolic dysfunction is providing a new ang...

Descripción completa

Detalles Bibliográficos
Autores principales: Munawar, Nayla, Ahmad, Aftab, Anwar, Munir Ahmad, Muhammad, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910761/
https://www.ncbi.nlm.nih.gov/pubmed/35269766
http://dx.doi.org/10.3390/ijms23052625
_version_ 1784666582098640896
author Munawar, Nayla
Ahmad, Aftab
Anwar, Munir Ahmad
Muhammad, Khalid
author_facet Munawar, Nayla
Ahmad, Aftab
Anwar, Munir Ahmad
Muhammad, Khalid
author_sort Munawar, Nayla
collection PubMed
description Schizophrenia (SCZ) is a psychotic syndrome with well-defined signs and symptoms but indecisive causes and effective treatment. Unknown underpinning reasons and no cure of the disease profoundly elevate the risk of illness. Gut microbial dysbiosis related metabolic dysfunction is providing a new angle to look at the potential causes and treatment options for schizophrenia. Because of the number of side effects, including gut dysbiosis, of traditional antipsychotic drugs, new alternative therapeutic options are under consideration. We propose that non-pharmacotherapy using biotherapeutic products could be a potent treatment to improve cognitive impairment and other symptoms of schizophrenia. Use of live microorganisms (probiotics), fibers (prebiotics), and polyphenols alone or in a mixture can maintain gut microbial diversity and improve the two-way relationship of the gut microbiota and the central nervous system. Fiber and polyphenol induced management of gut microbiota may positively influence the gut–brain axis by increasing the level of brain-derived neurotrophic factors involved in schizophrenia. Furthermore, we endorse the need for comprehensive clinical assessment and follow-up of psychobiotic (pro and prebiotics) treatment in mental illness to estimate the level of target recovery and disability reduction in schizophrenia.
format Online
Article
Text
id pubmed-8910761
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89107612022-03-11 Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia Munawar, Nayla Ahmad, Aftab Anwar, Munir Ahmad Muhammad, Khalid Int J Mol Sci Review Schizophrenia (SCZ) is a psychotic syndrome with well-defined signs and symptoms but indecisive causes and effective treatment. Unknown underpinning reasons and no cure of the disease profoundly elevate the risk of illness. Gut microbial dysbiosis related metabolic dysfunction is providing a new angle to look at the potential causes and treatment options for schizophrenia. Because of the number of side effects, including gut dysbiosis, of traditional antipsychotic drugs, new alternative therapeutic options are under consideration. We propose that non-pharmacotherapy using biotherapeutic products could be a potent treatment to improve cognitive impairment and other symptoms of schizophrenia. Use of live microorganisms (probiotics), fibers (prebiotics), and polyphenols alone or in a mixture can maintain gut microbial diversity and improve the two-way relationship of the gut microbiota and the central nervous system. Fiber and polyphenol induced management of gut microbiota may positively influence the gut–brain axis by increasing the level of brain-derived neurotrophic factors involved in schizophrenia. Furthermore, we endorse the need for comprehensive clinical assessment and follow-up of psychobiotic (pro and prebiotics) treatment in mental illness to estimate the level of target recovery and disability reduction in schizophrenia. MDPI 2022-02-27 /pmc/articles/PMC8910761/ /pubmed/35269766 http://dx.doi.org/10.3390/ijms23052625 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Munawar, Nayla
Ahmad, Aftab
Anwar, Munir Ahmad
Muhammad, Khalid
Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
title Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
title_full Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
title_fullStr Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
title_full_unstemmed Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
title_short Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
title_sort modulation of gut microbial diversity through non-pharmaceutical approaches to treat schizophrenia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910761/
https://www.ncbi.nlm.nih.gov/pubmed/35269766
http://dx.doi.org/10.3390/ijms23052625
work_keys_str_mv AT munawarnayla modulationofgutmicrobialdiversitythroughnonpharmaceuticalapproachestotreatschizophrenia
AT ahmadaftab modulationofgutmicrobialdiversitythroughnonpharmaceuticalapproachestotreatschizophrenia
AT anwarmunirahmad modulationofgutmicrobialdiversitythroughnonpharmaceuticalapproachestotreatschizophrenia
AT muhammadkhalid modulationofgutmicrobialdiversitythroughnonpharmaceuticalapproachestotreatschizophrenia